Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONWARDS 1: Once-weekly insulin icodec vs once-daily insulin glargine in insulin-naive type 2 diabetes
jRCT2031200241Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Dec 2020
- Modality
- Peptides
01
Overview
Phase 3, randomised, double-blind trial of insulin icodec in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Change in HbA1c from baseline to week 52. Started Dec 2020; status: completed.
02
Drugs
insulin icodec
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2031200241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200241.